Scourzic, Laurianne https://orcid.org/0000-0003-2875-1642
Izzo, Franco https://orcid.org/0000-0002-5813-6504
Teater, Matt
Polyzos, Alexander P. https://orcid.org/0000-0002-2509-9698
Cucereavii, Lucretia
Chin, Christopher R. https://orcid.org/0000-0002-2140-3197
Papin, Antonin
Pinto, Hugo B.
Mlynarczyk, Coraline https://orcid.org/0000-0002-6750-0240
Tsialta, Ioanna https://orcid.org/0009-0004-5666-775X
Xia, Min https://orcid.org/0000-0002-1093-5008
Lidoski, Abigail https://orcid.org/0009-0006-5348-4135
Myers, Robert M.
Israel, Eva M. https://orcid.org/0000-0001-9533-2881
Venturutti, Leandro
Mackay, Simon P.
Hoehn, Kenneth B.
Skoultchi, Arthur I.
Béguelin, Wendy https://orcid.org/0000-0002-4894-9229
Stadtfeld, Matthias https://orcid.org/0000-0002-5852-9906
Chen, Zhengming
Landau, Dan A.
Melnick, Ari M. https://orcid.org/0000-0002-8074-2287
Apostolou, Effie https://orcid.org/0000-0002-8111-0863
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (1R01CA283327)
Article History
Received: 26 November 2024
Accepted: 31 October 2025
First Online: 29 December 2025
Competing interests
: A.M.M. has research funding from Janssen, Epizyme and Daiichi Sankyo and has consulted for Exo Therapeutics, Treeline Biosciences, Astra Zeneca and Epizyme. K.B.H. has received consulting fees from Prellis Biologics. D.A.L. has received prior research funding from BMS, 10x Genomics and Illumina that is unrelated to the current paper. The other authors declare no competing interests.